Haiti vs Lebanon: Average cost of multi drug-resistant tuberculosis treatment
Haiti
1,098 constant 2022 US$
in 2024
Lebanon
1,020 constant 2022 US$
in 2024
Haiti rank
44th
Lebanon rank
47th
Average cost of multi drug-resistant tuberculosis treatment over time
- Haiti
- Lebanon
How they compare
Haiti currently reports 1,098 constant 2022 US$ against 1,020 constant 2022 US$ in Lebanon, a difference of 78 constant 2022 US$.
That makes Haiti's figure about 1.1 times Lebanon's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Lebanon ahead.
Haiti ranks 44th and Lebanon ranks 47th of 92 countries.
Across the 2 decades both report, Haiti averaged higher in 1 and Lebanon in 1.
Head to head by decade
| Decade | Haiti | Lebanon | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,248 constant 2022 US$ | 1,443 constant 2022 US$ | 195.33 constant 2022 US$ | Lebanon |
| 2020s | 3,048 constant 2022 US$ | 1,227 constant 2022 US$ | 1,822 constant 2022 US$ | Haiti |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Haiti or Lebanon?
- Haiti, at 1,098 constant 2022 US$ against 1,020 constant 2022 US$ in Lebanon as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Haiti and Lebanon?
- 78 constant 2022 US$, with Haiti ahead.
- How many years of comparable data are there for Haiti and Lebanon?
- 8 years are reported by both, from 2017 to 2024.
- How do Haiti and Lebanon rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Haiti ranks 44th and Lebanon ranks 47th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.